Prescription coverage gaps leave Alzheimer's caregivers paying more out of pocket and spending more time on paperwork, travel, and clinic visits. A coverage gap means a needed drug is not covered, needs approval first, or still carries a large share of the cost. Dementia caregivers already face higher drug and care costs than other caregivers. The gaps matter because Alzheimer's treatment often involves both daily prescriptions and clinic-based infusions with separate billing rules.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Where coverage breaks down
- What families actually pay
- What Medicare now covers, and its limits
- What caregivers can do before the pharmacy
Where coverage breaks down
Many maintenance drugs go through Medicare Part D. Even when a drug is listed, UsAgainstAlzheimer's notes that plans can require prior authorization or step therapy for certain conditions or populations. Caregivers must then request exceptions and file appeals.
Newer Alzheimer's infusions follow a different path. BenefitsUSA reports that Leqembi and Kisunla are covered under Part B as physician-administered infusions, not Part D, so patients face 20% coinsurance. Reported list prices near $26,500 per year for Leqembi and about $32,000 for Kisunla make that share large without supplemental coverage.
What families actually pay
An AARP Public Policy Institute survey found dementia caregivers spent $15,846 annually out of pocket in 2026, compared with $10,221 for other caregivers (AARP caregiver cost findings). Overall caregiver spending averaged $11,508. The difference shows how dementia adds prescription, supply, and service costs at once.
A U.S. Pharmacist summary of JAMA Network Open research reports higher total and out-of-pocket prescription spending for community-dwelling people with Alzheimer's and related dementias. Infusion logistics add unpaid labor. Modeling cited in the Journal of Alzheimer's Disease estimated $45,208 in medical costs plus $6,095 in caregiver time for chronic biweekly infusions, with visits averaging 2.3 hours plus 44 minutes of travel.
What Medicare now covers, and its limits
Medicare Part D now has an annual out-of-pocket cap. The Centers for Medicare & Medicaid Services set the cap at $2,000 for 2025 and $2,100 for 2026, replacing the old design that included the donut-hole coverage gap (final Part D redesign instructions). That limit helps with covered Part D drugs, but it does not fix Part B coinsurance or drugs a plan excludes.
Access to Leqembi is also narrow. The Centers for Medicare & Medicaid Services covers it broadly only for enrollees with mild cognitive impairment or mild dementia plus confirmed amyloid who are treated by a clinician in a CMS registry (broader Medicare coverage statement). Families outside those criteria may face denial or full self-pay.
What caregivers can do before the pharmacy
Support programs can ease coordination but not drug bills. The Centers for Medicare & Medicaid Services' GUIDE model funds care navigation and about $2,500 in yearly respite for eligible dementia families, but it does not pay Part B coinsurance or noncovered drugs (GUIDE model details). Caregivers must still check formularies, seek prior-authorization exceptions, and apply for Extra Help or Medigap.
- Check whether each drug is billed under Part D or Part B.
- Look up the plan formulary, prior-authorization rules, and exception steps.
- Ask the prescriber to document amyloid status, diagnosis stage, and medical need.
- Track denials, deadlines, and appeal letters in one folder.
- Ask about Extra Help, Medigap, respite funds, and clinic financial counselors.
